• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
- - - - -

Which likely the better cognition enhancer, EVN-6124 or SEN-12333?

evn-6124 sen-12333 nicotinic agonist h3 antagonist cognitive enhance novel nootropic

  • Please log in to reply
4 replies to this topic

#1 Christian Hunter

  • Guest
  • 21 posts
  • 4
  • Location:Austin, Texas

Posted 24 June 2014 - 11:29 AM


Between the two nicotinic agonists, which do you believe more likely to enhance cognition in otherwise healthy adults?

 

Lastly, do you believe either pose any material side-effect profile or toxicity risk?

 

Any additional thoughts welcome.

 

Christian Hunter

Austin, TX



#2 megatron

  • Guest
  • 608 posts
  • 79
  • Location:Norway
  • NO

Posted 24 June 2014 - 01:13 PM

I'm sure you mean EVP-6124. From the studies I've read, it would seem like GTS-21 has given the most significant improvements among the current modulators of the alpha-7 receptor tested in humans. 


  • like x 1

sponsored ad

  • Advert
Click HERE to rent this advertising spot for BRAIN HEALTH to support LongeCity (this will replace the google ad above).

#3 Christian Hunter

  • Topic Starter
  • Guest
  • 21 posts
  • 4
  • Location:Austin, Texas

Posted 24 June 2014 - 06:13 PM

I agree with you on GTS-21, but to my knowledge it can't yet be procured (w/ exception perhaps to to the group buy I've seen on this site), right?

 

And UGH, you're right, I meant "EVP-6124"; not sure if I can edit my original post but will look to do that now.   Thank you for your prompt reply.

 

My question to you however: do either EVP-6124 or SEN-12333 (WAY 317,538) interest you, and would you take either (or both) if handed the opportunity?

 

Thanks again, 

 

Christian Hunter

Austin, TX



#4 Flex

  • Guest
  • 1,629 posts
  • 149
  • Location:EU

Posted 25 June 2014 - 09:44 AM

From my amateurish knowledge I would use the partial agonist, so the EVP-6124.

 

The thing is this:

Partial agonists do activate ( in this case) a post-synapse to a certain extend, which can vary from, dont know, 10% to 90%,

depending on the molecule property.

If the activation is too low but the competitiveness is approximately as strong as the neurotransmitters, it would lead to a lesser activation i.e. decrease.

 

In contrast, the own body neurotransmitters do activate it to 100% like a full agonist. Which sounds good, but it is acompanied by a receptor desentisation.

The desensitation leads to a, so to say, callus which needs more and more neurotransmitters to activate the synapse to the same level as before accompanied with a receptor up or down regulation.

So this is one of several mechanisms of the homeostasis.

 

Btw: I heard that somkers do lost nicotinic synapses after a long period so arround 15 years. which differs from the usual receptor up/down regulation and is "afaik" kind of permanent.

 

To prevent a desentitaion and to ensure a longtermed effect, is either a cycling of the Full agonist needed (which is seemingly difficult)

or the usage of a partial agonist which shouldnt activate the synapse too much or too little.

 

Be aware that I could mistakenly told something wrong. So therefore I dont guarantee anything about those infromations.

 

 

 

 

 


Edited by Flex, 25 June 2014 - 09:50 AM.


sponsored ad

  • Advert
Click HERE to rent this advertising spot for BRAIN HEALTH to support LongeCity (this will replace the google ad above).

#5 medicineman

  • Guest
  • 750 posts
  • 125
  • Location:Kuwait

Posted 26 June 2014 - 11:54 PM

Continuous stimulation of Alpha 7 via beta amyloid is thought to be one of the causes of toxicity to the receptors themselves. I'd stick to partial agonists.





Also tagged with one or more of these keywords: evn-6124, sen-12333, nicotinic agonist, h3 antagonist, cognitive enhance, novel nootropic

4 user(s) are reading this topic

0 members, 4 guests, 0 anonymous users